Pages that link to "Q53334133"

The following pages link to Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. (Q53334133):

Displaying 40 items.

• The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Q28072596) (← links)
• Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey (Q30316569) (← links)
• Effects of music therapy and guided visual imagery on chemotherapy-induced anxiety and nausea-vomiting (Q30423316) (← links)
• Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers (Q34565988) (← links)
• The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life (Q34638379) (← links)
• Evidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forum (Q35572746) (← links)
• Efficacy and safety of electroacupuncture with different acupoints for chemotherapy-induced nausea and vomiting: study protocol for a randomized controlled trial (Q35654803) (← links)
• Symptom clusters in cancer patients: a review of the literature (Q36029730) (← links)
• Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial (Q36639416) (← links)
• Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer (Q36764063) (← links)
• Primary extraosseous Ewing sarcoma of the lung in children (Q36791086) (← links)
• Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK (Q37091366) (← links)
• A review of patient self-report tools for chemotherapy-induced nausea and vomiting (Q37190499) (← links)
• Integrative review of factors related to the nursing diagnosis nausea during antineoplastic chemotherapy (Q37347921) (← links)
• Antiemetic prescribing practices using a computerized physician order entry system (Q37697769) (← links)
• Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists (Q37736060) (← links)
• Tools for Assessing Nausea, Vomiting, and Retching (Q37824313) (← links)
• Use of high-dose cisplatin with aprepitant in an outpatient setting (Q37924902) (← links)
• Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review (Q38258166) (← links)
• Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis (Q38574240) (← links)
• Investigation of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy (Q38646159) (← links)
• EA versus sham acupuncture and no acupuncture for the control of acute and delayed chemotherapy-induced nausea and vomiting: a pilot study. (Q39001883) (← links)
• Translation and psychometric assessment of the Persian version of the Rhodes Index of Nausea, Vomiting and Retching (INVR) scale for the assessment of chemotherapy-induced nausea and vomiting. (Q39224398) (← links)
• Patient-practitioner perception gap in treatment-induced nausea and vomiting (Q40586658) (← links)
• Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study (Q41386185) (← links)
• Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. (Q42642028) (← links)
• A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre (Q43572875) (← links)
• Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States (Q45406696) (← links)
• Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Q46848063) (← links)
• Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy (Q47572599) (← links)
• Factors related to self-efficacy among men and women undergoing outpatient chemotherapy in Japan (Q47989036) (← links)
• Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting (Q48015419) (← links)
• Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study (Q48218900) (← links)
• Nausea and vomiting in diabetic and idiopathic gastroparesis (Q48535550) (← links)
• The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. (Q53228620) (← links)
• Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails. (Q53239014) (← links)
• Antiemetic activity of megestrol acetate in patients receiving chemotherapy (Q56690204) (← links)
• Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice (Q61822919) (← links)
• Reality of the emetogenic level of irinotecan (Q88427332) (← links)
• Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review (Q91972935) (← links)